In conclusion, neuron-released oligomeric αSyn-stimulated TLR2 may be responsible for PD pathogenesis, and LRRK2 inhibitors may be used as therapeutic drugs against neuroinflammation due to pathological αSyn propagation, as well as LRRK2-mediated pathology. Here, LRRK2 is linked to Parkinson disease.